Latest Approaches and Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer with Dr. Dorff скачать в хорошем качестве

Latest Approaches and Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer with Dr. Dorff

Tanya B. Dorff, MD, City of Hope, Duarte, California, explores the evolving treatment landscape for metastatic hormone-sensitive prostate cancer. In this 15-minute presentation, Dr. Dorf emphasizes the role of doublet and triplet therapies. Dr. Dorff highlights the survival benefits of androgen receptor pathway inhibitors and raises questions about the additional value of docetaxel in triplet regimens. She emphasizes tailoring treatment based on individual patient factors such as comorbidities, life expectancy, and concurrent medications rather than relying on a universal approach. She indicates that biomarker-driven strategies, such as decipher scoring, are gaining traction. Recent data shows improved outcomes with triplet therapy, especially in high-volume cases, but more evidence is needed to define its exact role. She also shares that lutetium PSMA therapy's potential benefit in earlier disease stages is also being explored with cautious optimism. Continued research into molecular stratification, treatment de-intensification, and rational sequencing strategies are crucial for improving outcomes. The importance of continued research into molecular stratification, treatment de-intensification, and rational sequencing strategies is emphasized as key to improving outcomes in this patient population. Don't forget to join the GRU Community: https://grandroundsinurology.com/regi... Follow us on Twitter/X: https://x.com/GRUrology And like and subscribe to us here on YouTube!